
A German court has dismissed the preliminary injunction against the sale of U.S. pharmaceutical company Merck (MSD)'s immunotherapy drug "Keytruda SC," which utilizes Alteogen's subcutaneous injection (SC) formulation conversion platform "HYBErozyme" (active ingredient ALT-B4).
Halozyme, which is engaged in a patent dispute with MSD, announced on its website news tab on the 19th (local time), "The German High Court has overturned the preliminary injunction order that halted the launch of Keytruda SC in Germany," adding, "We will immediately file a patent infringement lawsuit against Merck."
Previously, the German High Court had granted Halozyme's application for a preliminary injunction prohibiting the distribution and sale of Keytruda SC on grounds of patent infringement in December last year. With the court's ruling reversed after more than a year, it is expected that Keytruda SC can now be launched in Germany, Europe's largest pharmaceutical market.
Alteogen will receive up to $1 billion (approximately 1.33 trillion won) in milestones from MSD based on Keytruda SC sales, and after receiving all such payments, it will collect a royalty of 2% of net sales. As sales of Keytruda SC (U.S. product name: Keytruda Qlex) surge in the U.S. market, expectations are rising that the revenue structure and scale will change if sales in Europe, including Germany, begin to ramp up.
The German court's decision could also impact patent disputes in other European countries. In October last year, a Dutch court ruled that Keytruda SC infringes on Halozyme's patents. Consequently, the manufacture, launch, use, import, and inventory holding of Keytruda SC have been prohibited in eight countries: Belgium, Denmark, France, Ireland, Italy, Sweden, Switzerland, and the Netherlands.
In patent disputes within the U.S., rulings favorable to MSD, the manufacturer of Keytruda SC and Alteogen's partner, are accumulating. By mid-this month, MSD had secured "invalidity rulings" in all 14 "Post-Grant Review (PGR)" cases filed against Halozyme at the U.S. Patent Trial and Appeal Board (PTAB), where proceedings have been initiated.